<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860650</url>
  </required_header>
  <id_info>
    <org_study_id>CR108144</org_study_id>
    <secondary_id>VAC69120FLV1001</secondary_id>
    <nct_id>NCT02860650</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults</brief_title>
  <official_title>A Phase 1, First-in-human Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adult</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and
      Ad26.Filo as heterologous prime-boost vaccine regimens in healthy adult participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse events (AEs)</measure>
    <time_frame>Up to 28 days after the last vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Reactogenicity (ie, Solicited Local and Systemic Adverse Events)</measure>
    <time_frame>One Week after each study vaccine administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>Up to the end of long-term follow-up (Day 360)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binding Antibody Responses Against Ebola Virus (EBOV), Marburg Virus (MARV), and Sudan Virus (SUDV) Glycoproteins (GPs)</measure>
    <time_frame>Up to Day 360</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1: AD26.Filo/MVA-BN-Filo or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Ad26.Filo or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: MVA-BN-Filo/AD26.Filo or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: MVA-BN-Filo/AD26.Filo or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subset of Group 3: AD26.Filo or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first 8 participants in Group 3 who are willing to enroll in the subset for third vaccination, will receive a third vaccination at Day 92. Participants who previously received placebo will receive placebo a third time and participants who previously received MVA-BN-Filo/Ad26.Filo vaccination will receive Ad26.Filo as third vaccination. After enrollment of the 8 participants, the unblinded monitor and unblinded pharmacist will assess whether 7 participants who previously received MVA-BN-Filo/Ad26.Filo vaccination have been enrolled. If less than 7 participants of the active vaccine regimen have been enrolled, 2 additional participants will be enrolled. If at least 7 participants of the active vaccine regimen have been enrolled, no further will be enrolled. The aim is to enroll 7 or 8 participants who will receive Ad26.Filo as third vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Ad26.ZEBOV/MVA-BN-Filo or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.Filo</intervention_name>
    <description>Ad26.Filo intramuscular (IM) injection at a dose of 9*10^10 viral particles (vp).</description>
    <arm_group_label>Group 1: AD26.Filo/MVA-BN-Filo or Placebo</arm_group_label>
    <arm_group_label>Group 2: MVA-BN-Filo/AD26.Filo or Placebo</arm_group_label>
    <arm_group_label>Group 3: MVA-BN-Filo/AD26.Filo or Placebo</arm_group_label>
    <arm_group_label>Subset of Group 3: AD26.Filo or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-Filo</intervention_name>
    <description>MVA-BN-Filo intramuscular (IM) injection at a dose of 5*10^8 infectious units (Inf U).</description>
    <arm_group_label>Group 1: AD26.Filo/MVA-BN-Filo or Placebo</arm_group_label>
    <arm_group_label>Group 2: MVA-BN-Filo/AD26.Filo or Placebo</arm_group_label>
    <arm_group_label>Group 3: MVA-BN-Filo/AD26.Filo or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.ZEBOV</intervention_name>
    <description>Ad26.ZEBOV intramuscular (IM) injection at a dose of 5*10^10 vp.</description>
    <arm_group_label>Group 4: Ad26.ZEBOV/MVA-BN-Filo or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IM injection of 0.9 percent saline.</description>
    <arm_group_label>Group 1: AD26.Filo/MVA-BN-Filo or Placebo</arm_group_label>
    <arm_group_label>Group 2: MVA-BN-Filo/AD26.Filo or Placebo</arm_group_label>
    <arm_group_label>Group 3: MVA-BN-Filo/AD26.Filo or Placebo</arm_group_label>
    <arm_group_label>Subset of Group 3: AD26.Filo or Placebo</arm_group_label>
    <arm_group_label>Group 4: Ad26.ZEBOV/MVA-BN-Filo or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-Filo</intervention_name>
    <description>MVA-BN-Filo intramuscular (IM) injection at a dose of 1*10^8 Inf U.</description>
    <arm_group_label>Group 4: Ad26.ZEBOV/MVA-BN-Filo or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) of greater than or equal to (&gt;=) 18.5 and less than (&lt;) 35.0
             kilogram per square meter (kg/m^2)

          -  Healthy on the basis of physical examination, medical history, and the investigator's
             clinical judgment

          -  All women of childbearing potential must have a negative serum (beta-human chorionic
             gonadotropin [beta-hCG]) pregnancy test at screening, have a negative urine beta-hCG
             pregnancy test immediately prior to each study vaccine administration

          -  A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted
             reproduction from the start of screening onwards until at least 3 months after the
             last vaccination

          -  Participant must be available and willing to participate for the duration of the study
             visits and follow-up

        Exclusion Criteria:

          -  Has been vaccinated with a candidate filovirus vaccine

          -  Has received any Ad26- or MVA-based candidate vaccines in the past

          -  Has been diagnosed with disease caused by Ebola virus (EBOV), Marburg virus (MARV),
             Sudan virus (SUDV), or Ta√Ø Forest virus (TAFV) or exposed to EBOV, MARV, SUDV, or
             TAFV, including participants who traveled to epidemic filovirus areas in West Africa
             during the last 2 years (that is, since the start of the last Ebolavirus outbreak)
             should be excluded from the study

          -  Chronic active hepatitis B or hepatitis C infection, documented by hepatitis B surface
             antigen and hepatitis C antibody, respectively

          -  Acute illness (this does not include minor illnesses such as diarrhea or mild upper
             respiratory tract infection) or body temperature greater than or equal to (&gt;=) 38.0
             degree Celsius on Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

